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Kinase-mediated transcription, activators of nongenotropic
estrogen–like signaling (ANGELS), and osteoporosis: A dif-
ferent perspective on the HRT dilemma. Studies in bone, as
well as other nonreproductive target tissues of sex steroid,
like the cardiovascular and the central nervous system (CNS),
have elucidated a previously unappreciated mechanism of
sex steroid action involving the rapid activation of mitogen-
activated protein kinases and/or phosphatidyl inositol 3 ki-
nase, and consequent potent regulatory affects on the tran-
scription of a set of genes that is distinct from that regulated
through classic (genotropic) control of transcription. These
actions stem from an unexpected function of the classic nu-
clear receptors outside the nucleus, most probably from re-
ceptor interactions within distinct signal transduction pathways
in preassembled scaffolds. Importantly, these nongenotropic
actions are mediated by the ligand-binding domain of the re-
ceptor and can be functionally dissociated from classic tran-
scriptional activation with synthetic ligands, termed activators
of nongenotropic estrogen–like signaling (ANGELS). We high-
light this evidence and discuss its pharmacotherapeutic impli-
cations vis a vis the dilemmas posed by the recently appreciated
shortfalls of postmenopausal hormone replacement therapy.
Estrogens and androgens exert their effects through
receptor proteins, ligand-activated transcription factors
that belong to the superfamily of nuclear receptors
[1]. Binding of the ligand to the receptor protein
causes homo- or heterodimerization and conformational
changes that allow several coactivator proteins, many of
which possess intrinsic acetylase activity, to interact with
the receptor dimer. These complexes attach to specific
DNA response elements in target gene promoters, di-
rectly or through binding to other transcription factors
on the DNA. This causes histone acetylation, deconden-
sation of the chromatin, and initiation of transcription
(Fig. 1A). Alternatively, steroid nuclear receptors repress
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transcription by forming protein-protein complexes with
other transcription factors, thus preventing them from in-
teracting with their target gene promoters (Fig. 1B) [2].
Nonetheless, steroids, including estrogens and androgens,
also induce many rapid cellular responses that are in-
compatible with the genotropic models of receptor action
[3, 4].
Recent research into the actions of sex steroids on the
adult skeleton, the cardiovascular system, and the central
nervous system (CNS) has strongly suggested that, in con-
trast to reproductive tissues, in nonreproductive tissues,
the effects of these hormones are rarely a consequence
of the classic interaction between receptor and specific
DNA elements in target gene promoters [5]. Rather,
the effects result (1) from protein-protein interaction be-
tween the receptors and other transcription factors such
as nuclear factor-jB (NF-jB), activating protein-1 (AP-
1), or CCAAT enhancer binding protein (C/EBP), as
exemplified by the negative regulation of cytokines in-
volved in osteoclastogenesis [6, 7]; or (2) from rapid,
nongenotropic mechanisms of receptor action [8–11].
One of the best-documented nongenotropic actions of
estrogens in different cell types, including bone, endothe-
lial, and neuronal cells is the activation of the mitogen-
activated protein kinases (MAPKs) (Fig. 1C), or the phos-
phatidylinositol 3 kinase (PI3K).
THE MAP AND PI3 KINASES
MAPKs are Ser/Thr kinases that transduce chemical
and physical signals from the cell surface to the nucleus,
thereby controlling proliferation, differentiation, and
survival [12]. These enzymes are activated through tyro-
sine kinase receptors, such as those for epidermal growth
factor (EGF), insulin growth factor (IGF), or platelet-
derived growth factor (PDGF); G protein–coupled
receptors such as those for peptide hormones [e.g.,
parathyroid hormone (PTH), luteinizing-hormone
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Fig. 1. Genotropic and nongenotropic mode of estrogen receptor (ER) action. (A) Protein-DNA interaction of the ER in the case of the tran-
scriptional regulation of ERE-containing genes. (B) Protein-protein interaction responsible for the transcriptional regulation of genes that do not
contain ERE sites. (C) Nongenotropic action of the ER. 17b−estradiol (E2) binding to the ER (or a shorter splice variant) with the Src/Shc/ERK
and JNK signaling pathways. This event is followed by alteration of the activity of transcription factors, and transcription factor–dependent (up- or
down-) regulation of gene expression.
releasing hormone (LHRH) and thyrotropin-releasing
hormone (TRH)]; or through receptors activated by
diverse ligands, including lipids, bioactive amines, and
cytokines. Integrins, such as b1 and avb3, can also
activate MAPK.
MAPKs are grouped into subfamilies on the basis of
sequence similarity and mechanisms of upstream regula-
tion, the best-characterized of which are the extracellular
signal regulated kinases (ERK1/2), the jun N-terminal ki-
nases (JNKs), and the p38 kinases subfamilies. In general,
activation of ERK1/2 leads to cell survival, whereas acti-
vation of JNKs and p38 induce apoptosis. Both transient
and prolonged ERK activation can lead to either prolif-
eration or differentiation, perhaps depending on the cell
context [13]. Furthermore, a particular cell fate might de-
pend more on the dynamic balance between the different
MAPKs (and other signaling pathways) than on the acti-
vation of a particular subfamily [14].
The transduction of the signal from the cell surface re-
ceptors to the MAPKs begins with receptor activation
that leads to phosphorylation and recruitment of acces-
sory proteins, such as Ras, SOS, Src, and Shc (Fig. 1C).
This is followed by a three-step cascade leading to MAPK
activation by two intermediate kinases: a MAPK kinase
(e.g., MAPKK, MKK, or MEK) and a MAPKK kinase or
MEK kinase (e.g., MAPKKK or MEKK). The specificity
of MAPK activation is assured by several mechanisms,
including organization of the components of distinct cas-
cades within preassembled scaffolds, sequential physical
interactions between members of a given cascade, as well
as positive and negative feedback loops that result from
the regulation of the expression of both cell surface re-
ceptor ligands and inhibitors by the MAPKs [12]. The
recognition of specific substrates is accomplished through
physical interactions between extracatalytic domains of
the MAPKs and specific phosphoacceptor, or docking
sites on the specific substrates. Phosphorylation of sub-
strates by MAPKs can alter cellular functions through
changes in gene transcription, as in the phosphorylation
of transcription factors. Alternatively, phosphorylation
may alter cellular function by modifying the activity of
proteins, independent of any transcriptional changes.
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PI3 kinase, by phosphorylating both lipids and pro-
teins [15], regulates key cellular functions, such as pro-
liferation, differentiation, and survival. The survival-
promoting effects of PI3K result from the activation of a
downstream kinase, protein kinase B (PKB), also known
as Akt. PI3K activates PKB either by direct phospho-
rylation or by generating phosphatidyl inositols, which
activate PKB by binding to its pleckstrin homology do-
main.
One of the common phosphorylation targets of acti-
vated ERKs or PKB is the proapoptotic protein Bad,
a member of the Bcl-2 family of proteins that controls
release of caspase-activating factors from mitochondria.
Proapoptotic members form homo- or heterodimers with
antiapoptotic members such as Bcl-2 and Bcl-xL [16,
17]. Phosphorylation of Bad causes its inactivation and
thereby, dissociation from Bcl-2, which frees Bcl-2 to form
homodimers, preventing the release of caspase activators
[18].
ACTIVATION OF KINASES BY SEX STEROIDS
Both estrogens and androgens increase the phospho-
rylation of ERKs in osteoblasts and osteocytes, with a
peak at 5 minutes and return to baseline by 15 min-
utes, and down-regulate the phosphorylation of JNK1 in
the same cells [19, 20]. Activation of PI3K and a Src–
Shc–ERK signaling cascade, as well as suppression of
JNK via estrogen receptor (ER)a, ERb , or the andro-
gen receptor (AR), leads to downstream modulation of
the activity of the transcription factors Elk-1, C/EBPb ,
and CREB, or c-Jun/c-Fos, respectively, providing a link
between nongenotropic and genotropic functions of the
receptors [20, 21]. All these events are required
for the antiapoptotic effects of sex steroids on os-
teoblasts/osteocytes, as ERK activation and the protec-
tive effect of the steroids on apoptosis can be blocked
by specific inhibitors of Src and MEK, or by dominant-
negative mutants of Src, Shc, and MEK. Likewise, the
protective effect of these hormones can be abrogated by
dominant-negative mutants of PI3K and JNK1, as well as
Elk-1, C/EBPb , CREB, or c-Jun. Hence, the mechanism
of the antiapoptotic effect of sex steroids comprises a
three-stage cascade of events: (1) modulation of cytosolic
kinases (ERKs or JNK); (2) kinase-mediated alteration
of the activity of transcription factors; and (3) transcrip-
tion factor–dependent (up- or down-) regulation of gene
expression. All these effects can be demonstrated in bone
in vivo [20]. Interestingly, not only does the estrogen-
activated receptor stimulate MAPK and PI3K activity,
but activation of MAPKs or PI3K also induces estrogen-
independent transcriptional activation of the nuclear ER
[22–25].
As in bone cells, both estrogens and androgens acti-
vate ERKs in endothelial and smooth muscle cells, which
could explain several beneficial effects of sex steroids
on the cardiovascular system, including the relaxation of
coronary arteries, vasodilatation, and protection against
blood vessel injury from hypoxic insults [10]. Both estro-
gens and androgens also rapidly increase the production
of nitric oxide synthase in endothelial cells (eNOS) [26–
28]. eNOS activation by estrogens occurs in two phases,
both of which require kinase activation. The initial phase
results from ERK activation and lasts up to 10 minutes
[27]. The second phase is the result of the activation of the
PI3K-Akt pathway and lasts up to 30 minutes [29, 30]. In
addition to ERKs and PI3K, estrogens also activate the
p38 MAPKs in endothelial cells; and p38 activation has
been directly linked to the protection of endothelial cells
from hypoxia-induced apoptosis [31, 32].
Estrogens also cause a rapid and sustained activation of
ERKs in cerebral cortex explants, which is secondary to
an increase in B-raf and MEK kinase activity [33]. These
changes are probably responsible for estrogen decreasing
the risk of neurodegenerative diseases and attenuating
brain injury by suppressing the effects of neurotoxic or
ischemic stimuli [9, 11].
NOVEL FEATURES OF RECEPTOR ACTION
Elucidation of the mechanism of the activation of
MAPKs and PI3K by sex steroids has revealed unex-
pected functions and features of the nuclear receptors.
Whether these features are unique to the sex steroid
receptors, or are shared by other steroid receptors is
unknown.
Extranuclear actions in preassembled scaffolds
In studies with osteoblasts, osteocytes, embryonic fi-
broblasts, and HeLa cells, we found that activation of
the Src–Shc–ERK or suppression of the JNK pathways
and downstream modulation of ERK and JNK-induced
transcription by estrogens or androgens is nongenotropic
and requires only the ligand-binding domain (LBD) of
the ER, a region of the receptor that is distinct from
that responsible for the genotropic actions of the ligand-
activated protein [19, 20]. Furthermore, targeting this
LBD to the plasma membrane reproduced fully the ERK-
, JNK-, and PI3K-mediated antiapoptotic function of the
full-length ERa. By contrast, targeting this domain ex-
clusively to the cell nucleus resulted in complete loss of
its antiapoptotic activity. The Src kinase physically asso-
ciates with the ER or AR proteins [34, 35]. As in the
case of the Src–Shc–ERK pathway, PI3K activation re-
sults from direct interaction of the ER with the p85 reg-
ulatory subunit of the PI3K, and is independent of the
transcriptional activity of the receptor [30].
Several members of the MAPK signaling pathway, in-
cluding Src, Shc, and ERKs, are clustered in caveolae,
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specialized membrane invaginations that are enriched in
the scaffolding protein caveolin-1 and compartmentalize
signal transduction [36], and which are found in several
cell types, including neuronal, endothelial, and osteoblas-
tic cells [11, 37]. ERa has been shown to coimmunopre-
cipitate with caveolin-1 [38]. Furthermore, a subpopula-
tion of ERa has been colocalized in caveolae with both
caveolin and eNOS in human endothelial cells [26]. These
lines of evidence, together with the finding that the an-
tiapoptotic signal of the LBD of the ER is preserved
when this protein is targeted to the membrane but is lost
when targeting it to the nucleus, suggest strongly that
nongenotropic activation of signaling pathways by sex
steroids is mediated via the classic receptors, or perhaps
via a shortened spliced variant that is localized in the
membrane and, in particular, within caveolae. Razandi
et al [31] have shown that both ERa and ERb can be de-
tected in the cell membrane, that the membrane receptors
might be derived from the same transcripts as the nuclear
ones, and that a mutation that compromises the ability of
the receptor to localize to the membrane also abolishes
its nongenotropic actions [39]. They also showed that
a membrane-impermeable form of estrogen (E2-BSA)
rapidly activates the p38 MAPK and protects endothelial
cells from hypoxia-induced apoptosis [31, 32]. In agree-
ment with Razandi et al, both membrane-impermeable
estrogen and testosterone-BSA activate ERKs in os-
teoblasts and osteocytes, and thereby protect them from
apoptosis [8].
Relaxed gender specificity
In contrast to reproductive tissues, where develop-
ment, growth, maintenance, and function depend on
estrogens in females and androgens in males, in nonrepro-
ductive tissues, such as bone, the cardiovascular system,
and CNS, this specificity is greatly relaxed [5]. For exam-
ple, closure of the epiphyses of long bones is estrogen-
dependent in both sexes [40, 41]. Further, estrogens can
restore bone mass in males with androgen deficiency [42,
43], whereas nonaromatizable androgens can protect the
female skeleton against the adverse effects of estrogen
deficiency [43–50]. Some of these paradoxical effects can
be explained by the similar distribution of sex steroid re-
ceptors in the nonreproductive tissues of both sexes.
The nongenotropic Src–Shc–ERK– and JNK-mediated
antiapoptotic effect of estrogens or androgens on os-
teoblasts and osteocytes is transmitted by the ERa, ERb ,
or the AR with similar efficiency, irrespective of whether
the ligand is an estrogen or an androgen [19]. Further-
more, both estrogens and nonaromatizable androgens
promote osteoclast apoptosis and suppress osteoclast
formation from bone marrow progenitors in a gender-
independent manner [51]. In other words, estradiol or
dihydrotestosterone (DHT) are equally effective, irre-
spective of the sex from which the osteoclasts were
derived. Furthermore, the proapoptotic effect of sex
steroids on osteoclasts is inhibited by heterologous recep-
tor antagonists. These mechanistic features suggest that
the opposite effects of sex steroids on osteoblast and os-
teoclast apoptosis are mediated via similar mechanisms,
and in both cases, are independent of gender. Consistent
with these findings, estrogens or nonaromatizable andro-
gens activate eNOS in endothelial cells in vitro, irrespec-
tive of the gender of the cell donor (P. Shaul, personal
communication). Gender-independent signaling through
the ERs or ARs might also account for the neuroprotec-
tive effects of estrogen in males and androgen in females
[52]. It is therefore plausible that gender-independent
signaling potentially resulting from relaxed specificity in
ligand-receptor intersection [53], might provide an addi-
tional mechanistic basis for the relaxed gender specificity
of these effects [53].
Dissociation of the genotropic from the nongenotropic
function of the nuclear receptors with novel synthetic
ligands
A most striking and unexpected result of the elucida-
tion of the nongenotropic regulation of kinases by classic
sex steroid receptors is that ERK activation and the re-
sulting prevention of apoptosis can be dissociated from
the transcriptional activity of the nuclear receptors with
synthetic ligands [19]. By comparing the effects of various
ligands on the transcription of the complement compo-
nent C3 gene, which contains an ERE in its promoter,
and is regulated by estrogen in a classic manner (or on
the transcriptional activation of an ERE-driven promoter
or on the IL-6 promoter), with their antiapoptotic ef-
fect on primary calvarial cells, we have demonstrated
that 4-estren-3a,17b-diol (estren), a four-ring steroid
analog with minimal transcriptional activity (1000-fold
lower than that of estradiol), exhibits potent antiapop-
totic efficacy. However, a 1,3,5-tris(4-hydroxylphenyl)-
4-propylpyrazole (pyrazole) with potent transcriptional
activity has minimal antiapoptotic efficacy. The relative
antiapoptotic potency of these two compounds corre-
lates with their ability to induce ERK phosphorylation
[19]. Strikingly, in studies on osteoclasts, estren could
stimulate apoptosis in cells from males or females and
suppress osteoclast formation from bone marrow pro-
genitors, whereas pyrazole was ineffective, strongly sup-
porting the contention that a nongenotropic mechanism
of receptor action (albeit, different downstream signal-
ing pathways) is responsible for both the anti- and the
proapoptotic effects of sex steroids on bone cells [51].
Estren stimulates kinase-mediated transcription at three
to four orders of magnitude lower concentrations than
those required for classic genotropic transcription, the
latter corresponding to its weak binding affinity for
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the ER or AR (300-fold lower than estradiol and 40-
fold lower than R1881, respectively) in conventional
equilibrium assays. Most unexpectedly, estren increased
hindlimb bone mineral density and the mechanical
strength of the axial and appendicular skeleton in both
female and male mice, not only significantly more than
estradiol or DHT, but also above the BMD of the
estrogen-replete control animals. Yet, estren, unlike
estradiol or DHT replacement, did not affect the weight
of female or male reproductive organs [54]. This unique
biologic profile evidently results from kinase-mediated
up- or down-regulation of a set of genes that is distinct
from that regulated by the classic ligands [20].
Estrogens rapidly activate MAPK and PI3K in breast
cancer cells via a nongenotropic mechanism of receptor
action. Identical to the case of bone cells, this can be ac-
commodated by the LBD of the ER, and is clearly the
result of an extranuclear receptor action, as it can be
readily demonstrated when the LBD of the ER is local-
ized in the cell membrane but not in the nucleus [55]. In
breast cancer cells, the membrane-associated ER signals
through G-protein–coupled receptors to activate EGFR
and downstream kinase signaling cascades that influence
both classic transcriptional and nongenotropic actions of
estrogen in breast cancer cells (for a review, see [56]). The
relative contribution of nongenotropic and, in particular,
MAPK activation, versus the genotropic actions of these
receptors to breast cancer cell growth remains unclear.
Nonetheless, existing evidence and our studies [54] sug-
gest that the mitogenic effects of estrogen might be due
primarily to genotropic actions, as MCF-7 cells resulting
from increased transcription of the immediate response
genes c-fos, c-myc, and pS2, are mediated by cyclins, and
are independent of ERK activation [57–62]. Moreover, a
cis-element decoy against the estrogen response element
of the ER disrupts the genotropic actions of the receptor,
ablates proliferation, and promotes apoptosis of human
breast cancer cells without affecting estradiol-induced
activation of ERKs [63]. In agreement with the lat-
ter observations, pyrazole, like 17b-estradiol, was found
to stimulate MCF-7 cell proliferation, as measured by
thymidine incorporation, whereas estren did not [54].
Hence, ANGELS might circumvent the risk of malignan-
cies during postreproductive life [8].
PHARMACOTHERAPEUTIC OPPORTUNITIES
Estrogens and androgens influence the linear growth
of bones during puberty. In addition, they maintain
homeostasis of the adult skeleton during the continuous
process of bone remodeling. Linear skeletal growth is
governed by the chondrocytes of the growth plate. Main-
tenance of adult bone mass is controlled by the basic mul-
ticellular units (BMUs)—temporary anatomic structures
comprising osteoclasts in the front and osteoblasts in the
rear. Bone remodeling consists of focal cycles of resorp-
tion followed by formation. The rate of remodeling de-
pends on the number of cycles, but the effects on bone
mass depend on the focal balance within each cycle.
Estrogens and androgens decrease the number of
remodeling cycles by attenuating the birth rate of osteo-
clasts and osteoblasts, in part by regulating the produc-
tion of cytokines [64–66]. Consequently, loss of estrogens
in females or androgens in males after maturity leads
to an increased rate of bone remodeling. However, in-
creased remodeling alone cannot explain why loss of sex
steroids tilts the balance of resorption and formation in
favor of the former. Evidently, the focal balance between
resorption and formation depends on the lifespan of
osteoclasts and osteoblasts, reflecting the timing of apop-
tosis. Apoptosis of osteoclasts and osteoblasts is mod-
ulated by sex steroids in opposite directions. Consistent
with the antiapoptotic effect of sex steroids on osteoblasts
and osteocytes, estrogen deficiency in mice, rats, and
humans increases the prevalence of osteoblastic osteo-
cytic cell apoptosis [19]. Conversely, estrogen deficiency
prolongs the survival of osteoclasts—a phenomenon con-
sistent with proapoptotic effects of sex steroids on osteo-
clasts [67]. Shortening of the lifespan of bone-forming
cells in combination with prolongation of the lifespan of
bone-resorbing cells provides an explanation for the tilt
of the focal balance between formation and resorption in
favor of the latter; hence, loss of bone and the develop-
ment of osteoporosis [8].
Decreased ovarian function at menopause is a major
factor for the development of osteoporosis, and perhaps
coronary artery disease, stroke, and neurodegenerative
diseases. However, continuous exposure of reproductive
tissues to estrogen during the postreproductive part of life
is a risk factor for the development of breast, ovarian, and
uterine cancers [5, 68]. The two highly publicized large,
prospective, randomized placebo-controlled clinical tri-
als, known as the Women’s Health Initiative (WHI), doc-
umented the antiosteoporotic efficacy of postmenopausal
hormone replacement in the general population at large
(i.e., subjects with and without osteoporosis). However,
the results of WHI not only confirmed the increased in-
cidence of breast cancer in women receiving estrogen-
progestin replacement therapy, but also revealed for the
first time an unexpected increase in the incidence of
cardiovascular complications, including coronary heart
disease, stroke, and venous thromboembolism in the
treatment group. This surprising development had a pro-
found impact on the practice of medicine, leading to the
recommendation that hormone therapy should be re-
stricted only for the management of menopausal symp-
toms and for the shortest duration possible. Moreover,
the WHI reinforced the need for synthetic ligands of the
ER that exhibit estrogenic activity in a tissue-selective
manner: acting as estrogen agonists in bone, but as
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estrogen antagonists (or completely devoid of estrogenic
activity) in breast, uterus, and ovaries. Several of these so-
called selective estrogen receptor modulators (SERMs)
have been identified, and one, raloxifene, has been ap-
proved for the prevention and management of osteoporo-
sis by the FDA since 1998 [2].
The possibility of dissociating MAPK activation and
the resulting prevention of apoptosis from the genotropic
activity of the ER provided for the first time the oppor-
tunity to consider mechanism-specific ligands of the ERs
or the AR [rather than tissue-specific ligands (SERMs)
or classic estrogens or androgens] for pharmacotherapy.
The potential of this approach is strongly supported by
the discovery that, while inactivation of the glucocorti-
coid receptor caused lethality in mutant mice, elimination
of the transcriptional activity of this receptor did not—
literally a difference between life and death [69].
We have coined the term ANGELS for ER ligands that
activate nongenotropic estrogen–like signaling, but that
lack, at least partially, the ability to induce the classic tran-
scriptional activity of the ER [8]. A prototypic compound
for ANGELS is the four-ring synthetic steroid analog es-
tren of the reports by Kousteni et al [19, 20, 54].
Anabolic versus antiresorptive bone therapies
Until recently, all approved drugs for the preven-
tion and treatment of osteoporosis—bisphosphonates, es-
trogens, raloxifene, and calcitonin—were antiresorptive
agents, decreasing the lifespan of mature osteoclasts, as
well as the development of osteoclast progenitors and/or
the recruitment and function of osteoclasts. Because os-
teoclastic bone resorption and osteoblastic bone forma-
tion are inexorably linked during the remodeling of the
adult skeleton, antiresorptive agents slow the rate of bone
remodeling [8]. In several instances, this is sufficient to
prevent or slow the rate of postmenopausal bone loss.
Even in the pre-WHI era in the United States, less than
7% of estrogen-deficient women with osteoporosis re-
ceived hormone replacement therapy. And, of those who
did, only 30% stayed on it long enough to enjoy its ben-
efits during their late 60s and 70s, when the incidence of
the most serious bone fracture (hip) reaches its peak [70,
71]. It is obvious that the optimal therapeutic modality
for osteoporosis, especially in patients who have already
suffered significant bone loss, is an anabolic agent that
can restore bone mass by rebuilding bone within a short
period of time. Bisphosphonates, and to a lesser extent
estrogens, cause a small increase in apparent BMD be-
cause resorption precedes formation by several weeks,
and the remodeling space temporarily contracts. The an-
tiapoptotic effects of such compounds on osteoblasts and
osteocytes might contribute to their anti-fracture efficacy,
which is disproportionate to their effects on BMD [8, 72].
In November of 2002, the FDA approved daily parathy-
roid hormone (PTH) injections as the first and currently,
the only one therapy for osteoporosis that can truly re-
store bone mass after it is lost—a so-called anabolic ther-
apy. Indeed, several clinical trials with PTH injections
have now clearly demonstrated the ability of this regimen
to restore BMD to its normal range, reducing bone frac-
tures much more effectively than antiresorptive agents
within one to two years of treatment [73]. Work from
our group has elucidated that the ability of PTH to in-
crease bone mass by rebuilding bone evidently results
from an increase in the lifespan of mature osteoblasts in
vivo by reducing the prevalence of their apoptosis, not
by increasing the generation of new osteoblasts or the
proliferation of existing ones [74, 75]. In line with this ev-
idence, it has become increasingly apparent over the last
few years that, indeed, osteoblast lifespan is an important
determinant of osteoblast number, bone formation rate,
and bone mass in health and disease; as well as a critical
mechanism of drugs used for the treatment of osteoporo-
sis [8, 76]. For example, besides intermittent PTH, at-
tenuation of osteoblast apoptosis contributes to the high
bone mass of humans and rodents caused by mutations
of the low-density lipoprotein receptor-related protein
[77], the osteosclerotic phenotype of sclerostin deficiency
(personal communication from Dr. Socrates Papapou-
los), the bone-protective effects of estrogen and andro-
gen [54], as well as the anabolic effect of prostaglandins
[78].
Because PTH injection or prostaglandins increase
bone mass without slowing remodeling, we reasoned ear-
lier that ER ligands with antiapoptotic, but not antire-
modeling, properties will expand the pool of mature
osteoblasts at sites of new bone formation, and allow
these cells more time to make bone to a much greater
degree than the antiresorptive agents that also slow re-
modeling [8]. Most surprisingly, we have more recently
determined that at least part of the superior effects of es-
tren on bone, compared to classic sex steroids, and their
potential to cause positive focal balance between forma-
tion and resorption and continuous gain in bone mass,
as distinguished from the antiremodeling/anticatabolic
effects of estrogens, most likely result from potentia-
tion of both Wnt and BMP signaling [79, 80]. Briefly,
we have found that estren decreases the Wnt antag-
onist Dickkopf-1, increases Wnt-1 and Wnt-2 expres-
sion, potentiates Wnt/b-catenin-mediated transcription,
and also increases BMP-2 expression and Smad phos-
phorylation. Consistent with these effects, estren induces
commitment of pluripotent mesenchymal progenitors,
and promotes differentiation of committed osteoblastic
cells toward the osteoblastic lineage, in an Src-, PI3K-,
and JNK-dependent manner. Estradiol, DHT, or 19-
nortestosterone, a potential androgenic metabolite of
estren, at concentrations as much as five orders of
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magnitude higher than ANGELS do not exhibit
these properties, perhaps because of counter-regulatory
genotropic actions. These observations indicate that the
mechanism-specific ligands of the ERs or the AR that we
have termed ANGELS, as distinct from tissue-specific lig-
ands (SERMs) or the sex steroids, do indeed represent a
truly anabolic and gender-neutral class of pharmacother-
apeutic agents for the management of osteopenic states
[19, 20, 54].
Several reasons encourage us to speculate that dur-
ing postreproductive life, this class of compounds might
be a more rational and advantageous candidate not just
for the treatment of osteoporosis but for the other pre-
sumed beneficial effects of estrogens on the cardiovas-
cular, neuronal, gastrointestinal, and immune systems
[81]: (1) nonreproductive tissues express lower levels
of receptors compared with reproductive tissues (10- to
50-fold), which might be sufficient for accommodating
nongenotropic actions of sex steroids, but is insufficient
for genotropic actions [5, 82]; (2) the levels of the ER or
AR in nonreproductive tissues do not vary from males to
females, which could account, at least in part, for the re-
laxed gender specificity of the response to the sex steroids.
Hence, nonreproductive tissues might be ideal targets for
gender-neutral ligands; (3) most importantly, unlike re-
productive tissues, in which the majority of estrogenic
effects are mediated via transcriptional activation, in non-
reproductive tissues, the predominant mechanism of ER
action seems to be nongenotropic (for a review see [5]).
CONCLUSION
ERs and the AR, and perhaps receptors for other mem-
bers of the same family of steroid receptor proteins, have
at least two different functions: one as transcription fac-
tors within the nucleus, and one as regulators of signaling
from the cell membrane to its nucleus. Acting as tran-
scription factors, these receptors might be the principal
regulators of the development, growth, and function of
reproductive tissues. As signal regulators, however, they
might be the principal regulators of organs and tissues
not directly related to procreation. Elucidating the dual
function of sex steroid receptors has important pharma-
cologic implications. Synthetic ligands of the ER that can
evoke the nongenotropic but not the genotropic signal
are bone anabolic agents, as opposed to natural estro-
gens or SERMs, which are antiresorptive (antiremod-
eling) agents. Such ligands might also circumvent the
side effects associated with conventional HRT. Indeed,
if nongenotropic effects of estrogen are as important in
other nonreproductive tissues as the evidence suggests,
ANGELS might also retain at least some of the benefi-
cial effects of estrogens on the vasomotor, cardiovascular
system, and CNS.
HRT during postreproductive life is a therapy whose
benefits derive primarily from estrogen actions on non-
reproductive tissues, whereas its side effects result from
actions on reproductive ones. Therefore, ligands that
can activate only the nongenotropic function of the ER
(or AR), as opposed to activating both genotropic and
nongenotropic functions in all tissues (i.e., natural estro-
gens) or both functions in some tissues selectively (i.e.,
SERMs), represent exciting new tools for an improved
HRT. We recognize that this approach might not be sim-
ple; however, tissue selectivity has not been that simple
either.
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